TB 2016
Durban, South Africa
July 16-17, 2016
The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Chair: Valerie Mizrahi, University of Cape Town

Welcome address
Aaron Motsoaledi, Minister of Health of South Africa

Why TB 2016? Why now?
Jens Lundgren, University of Copenhagen, International AIDS Society

Joining the TB and HIV global communities
José Luis Castro, International Union Against Tuberculosis and Lung Disease

Universal health care: The key to ending TB by 2030?
Eric Goosby, UN Special Envoy for TB

The role of communities in responding to the global TB epidemic
Thokozile Phiri, Facilitators of Community Transformation

10:00 - 11:30 | PLENARY SESSION | SESSION ROOM 12

Chairs: Zelalem Temesgen, Mayo Clinic and Anneke Hesseling, Desmond Tutu TB Centre, University of Cape Town

Understanding the biology of tuberculosis and its impact on drug discovery and development
Clifton Barry, National Institute of Allergy and Infectious Diseases

Critical questions and new approaches in TB vaccinology
Willem Hanekom, Bill & Melinda Gates Foundation

How latent is latent TB?
Robert Wilkinson, Crick Institute and University of Cape Town

Using rights to health and scientific progress to advance TB research and access
Mike Frick, Treatment Action Group

11:45 - 13:00 | BREAKOUT SESSIONS

SESSION ROOM 12 | BREAKOUT SESSION 1: NEW APPROACHES IN PREVENTION RESEARCH

Chairs: Gilla Kaplan, Bill & Melinda Gates Foundation and Diane Havlir, University of California, San Francisco

Towards a correlate of protective immunity to TB
David Russell, Cornell University

Potential indications and target populations for a new TB vaccine
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town

Drivers of tuberculosis transmission
Robin Wood, Desmond Tutu HIV Centre, University of Cape Town

Serial Quantiferon testing predicts disease risk among infants in high-transmission settings
Jason Andrews, Stanford University School of Medicine

SESSION ROOM 10 | BREAKOUT SESSION 2: ENDING TB DRUG SHORTAGES

Chairs: Lucica Ditiu, Stop TB Partnership and Sharonann Lynch, Doctors Without Borders

Addressing roles of GDF and tools to prevent and mitigate drug shortages
Brenda Waning, Global Drug Facility

Supply challenges in endemic settings
Welile Sikhondze, National TB Control Program, Ministry of Health, Swaziland

Supply challenges in the US
Neha Shah, United States Centers for Disease Control and Prevention

The impact of supply shortages on people living with TB
Julia Kalancha, AIDS Healthcare Foundation Ukraine
SESSION ROOM 12 | ABSTRACT SESSION 1: MDR AND XDR: DIAGNOSIS AND IMPACT

Chairs: Gavin Churchyard, The Aurum Institute and Neil Martinson, Perinatal HIV Research Unit

Abstract No. O05 Higher cost of implementing Xpert MTB/RIF in peripheral settings in Uganda: Implications for cost-effectiveness

Abstract No. O06 Large-scale expansion of drug-resistant tuberculosis case-finding in Mumbai via private provider engagement
R. Chopra, S. Vijayan

Abstract No. O07 Development of a reporter mycobacteriophage assay to detect emergent drug resistant MTB subpopulations
L. Uccellini, M. Larsen, P. Jain, A. Pym, V. Munsamy, M. O'Donnell

Abstract No. O08 Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, KwaZulu-Natal South Africa

SESSION ROOM 10 | ABSTRACT SESSION 2: PREVENTION OF HIV-ASSOCIATED TB

Chair: Jason Andrews, Stanford University

Abstract No. O13 Effectiveness and feasibility of implementation of isoniazid preventive therapy for HIV infected children attending ART clinics in India

Abstract No. O15 Effectiveness of isoniazid preventive therapy in reducing incidence of tuberculosis among PLHIV in programme settings in India

Abstract No. O16 HIV viral load as an independent risk factor for tuberculosis in South Africa

Abstract No. O14 Detection and characterisation of mycobacterium tuberculosis-specific CD4+ T cells using MHC class II tetramers in latent TB infection
N. Strickland, C. Riou, T. Scriba, R.J. Wilkinson, W.A. Burgers
15:15 - 16:30 | BREAKOUT SESSIONS

SESSION ROOM 12 | BREAKOUT SESSION 3:
UNDERSTANDING AND INTERVENCING IN PROGRESSION FROM INFECTION TO DISEASE

Chairs: Richard Chaisson, Johns Hopkins University and Robert Wilkinson, Crick Institute and University of Cape Town

Advantage of rifamycin containing regimens over isoniazid in high transmission settings: What is the evidence?
Tom Sumner, London School of Hygiene & Tropical Medicine

Advances in LTBI regimens: An update on ongoing clinical trials
Tim Sterling, Vanderbilt Tuberculosis Center

Are there lessons for TB from long-acting ART?
Sue Swindells, University of Nebraska Medical Center

Abstract No. O21 High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: The RAFA trial results
Corinne Simone Merle, WHO

SESSION ROOM 10 | BREAKOUT SESSION 4:
TRANSITIONING FROM RESEARCH AND DEVELOPMENT TO ACCESS FOR CHILDREN WITH TB


Filling research gaps for children with TB
Jennifer Furin, Case Western Reserve University

Developing and registering pediatric formulations for TB
Vijay Agarwal, Macleods

Programme considerations for integrating new tools
John Ditekemena, Elizabeth Glaser Pediatric AIDS Foundation

16:45 - 18:00 | BREAKOUT SESSIONS

SESSION ROOM 12 | BREAKOUT SESSION 5:
TB DRUG DISCOVERY AND DEVELOPMENT – WHERE ARE WE HEADING?

Chairs: Clifton Barry, National Institute of Allergy and Infectious Diseases and Luis Soto-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Opportunities and challenges in TB drug discovery:
Lessons from the benzothiazinones
Stewart Cole, École Polytechnique Fédérale de Lausanne

Lesion penetration as a critical determinant of TB drug efficacy
Rada Savic, University of California, San Francisco

Prospects for antimicrobial drug repurposing
David Barros, GlaxoSmithKline

Novel pathways for host-targeted therapy
Jerrold Ellner, Boston University

SESSION ROOM 10 | BREAKOUT SESSION 6:
ALIGNING AND ACHIEVING TARGETS FOR HIV/ AIDS AND TB CONTROL

Chairs: Joanne Carter, RESULTS and Michael Kimerling, KNCV Foundation

90-90-90 Targets for TB
Paula Fujiwara, International Union Against Tuberculosis and Lung Disease

Aligning HIV & TB targets in Eastern Europe and Central Asia
Michel Kazatchkine, UN Special Envoy on HIV/AIDS in Eastern Europe and Central Asia

Vital gaps in reaching TB targets
Shannon Hader, United States Centers for Disease Control and Prevention

Innovative financing in the fight to end TB
Lelio Marmora, UNITAID
**SESSION ROOM 10 | ABSTRACT SESSION 4: PAEDIATRIC MDR TB AND CLINICAL EPIDEMIOLOGY**

**Chairs:** Paula Fujiwara, International Union Against Tuberculosis and Lung Disease and Kevin Cain, Kenya Medical Research Institute

**Abstract No. O12 Treatment of multidrug-resistant tuberculosis (MDR-TB) in children and adolescents with a 9-month regimen in Africa**

**Abstract No. O11 Safety and tolerability of levofloxacin in HIV-infected and –uninfected children treated for multidrug-resistant tuberculosis**
A. Garcia-Prats, H. Draper, H. Finlayson, J. Winckler, A. Burger, H.S. Schaaf, A. Hesseling

**Abstract No. O10 Spatio-temporal clustering of drug-resistant tuberculosis in KwaZulu-Natal, South Africa 2004-2010**
A. Wolf, N. Padayatchi, B. Mathema, K. Naidoo, I. Master, G. Osborn, M. O’Donnell

**Abstract No. O09 Diabetes and tuberculosis in Korean men and women: Impact on tuberculosis incidence, recurrence and mortality**
J. Golub, Y. Mok, S. Hong, K.J. Jung, J. Samet, S.H. Jee

---

**SESSION ROOM 12 | ABSTRACT SESSION 3: TRANSMISSION AND DIAGNOSIS**

**Chairs:** Anton Pozniak, Chelsea & Westminster NHS Trust and Stewart Cole, École Polytechnique Fédérale de Lausanne

**Abstract No. O17 Deterministic linkage to evaluate the burden of recurrent TB disease in Cape Town, South Africa**
S. Hermans, N. Zinyakatira, J. Caldwell, F. Cobelens, A. Boulle, R. Wood

**Abstract No. O18 Mycobacterium tuberculosis molecular screening assay with sensitivity equivalent to culture**
J. Reed, Z. Walker, D. Basu, S. McFall

**Abstract No. O20 Development of a multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs in small hair samples**
R. Gerona, A. Wen, C. Koss, P. Bacchetti, M. Gandhi, J. Metcalfe

**Abstract No. O19 Diagnostic accuracy of Xpert®MTB/Rif, experience at district hospital of Buenos Aires for tuberculosis diagnosis**
M. Gismondi, T. Estrada, M. Rey, G. Ben, O. Sued, S. Tutzer, S. Kaufman, H. Perez
SESSION ROOM 12 | BREAKOUT SESSION 7:
MDR/XDR TB

Chairs: Daria Podlekareva, Nordsjaellands Hospital, Hilleroed and Rigshospitalet and Robin Wood, Desmond Tutu HIV Centre

Evolution of drug resistance in KwaZulu-Natal and implications for TB control
Alex Pym, KwaZulu-Natal Research Institute for Tuberculosis and HIV

Advances in improving treatment outcomes for MDR/XDR TB
Gunar Günther, University of Namibia School of Medicine

Diagnostic advances in MDR/XDR TB and their impact on clinical outcomes
Susan Dorman, Johns Hopkins University

Decentralization of MDR-TB: A case study from South Africa
Virginia de Azavedo, City of Cape Town

SESSION ROOM 10 | BREAKOUT SESSION 8:
HUMAN RIGHTS AND TB RESEARCH: REALIZING THE RIGHT TO SCIENTIFIC PROGRESS FOR TB

Chairs: Erica Lessem, Treatment Action Group and Diana Elizabeth Weil, WHO

Returning to Durban: Science, human rights and activism at the centre of the TB/HIV epidemics
Eric Goosby, UN Special Envoy for TB

Developing a rights-based approach to TB: concepts, case law and legislation
Brian Citro, International Human Rights Clinic, University of Chicago Law School

Incorporating community voices into TB science and programme
Ketholelie Angami, Nagaland Users Network

Using the law to safeguard rights of TB patients
Allan Maleche, Kenya Legal and Ethical Issues Network

13:00 - 14:00 BREAK & POSTER VIEWING

14:00 - 14:30 | KEYNOTE ADDRESS | SESSION ROOM 12

Chair: Owen Ryan, International AIDS Society

TB and HIV: A call to action
Stephen Lewis, AIDS-Free World
14:45 - 16:00 | BREAKOUT & ABSTRACT SESSIONS

SESSION ROOM 12 | BREAKOUT SESSION 9: DIAGNOSTICS & BIOMARKERS

Chairs: Robert Wallis, The Aurum Institute and Graeme Meintjes, University of Cape Town

Lessons from the rollout of Xpert MTB/RIF in South Africa
Wendy Stevens, National Health Laboratory Service South Africa

RePORT International: Advancing TB research using a common platform across global networks
Carol Hamilton, Duke University

Biomarkers with diagnostic accuracy in persons suspected for active TB
Jayne Sutherland, MRC Unit The Gambia

Novel biomarkers for monitoring treatment response
Gerhard Walzl, Stellenbosch University

SESSION ROOM 10 | ABSTRACT SESSION 5: COMMUNITY ENGAGEMENT AND INNOVATIONS

Chairs: Erica Lessem, Treatment Action Group and Lucica Ditiu, Stop TB Partnership

Abstract No. O03 Integrating HIV and TB interventions in the community to increase TB and HIV case detection, treatment adherence and TB treatment completion in Malawi and Zimbabwe
S. Sah, O. Guerrero, S. Lamb

Abstract No. O04 Anticorruption actions by patients in Ukraine impact on access to TB treatment
O. Stefanyszyna, I. Boyko

Abstract No. O02 Social support to TB patients by forming Self Health Group (SHG) and facilitating skill development for sustainable livelihoods
A. Trivedi, K. Sagili, N. Kumar, S. Kumar, A. Kumar, B. Kumar, S. Prasad

Abstract No. O01 Community advisory boards on repeat: What’s missing from TB clinical trials protocols
L. McKenna, M. Frick, C. Lee, M. Low, D. Namutamba, W. Vandevelde, E. Lessem

16:15 - 17:45 | CLOSING SESSION | SESSION ROOM 12

Chair: Haileyesus Getahun, WHO

Closing keynote: Trevor Mundel, Bill & Melinda Gates Foundation

Best poster award

Panel discussion: Leadership in the fight to end TB
Moderator: Nick Herbert, Member of Parliament, United Kingdom
Panelists: Parliamentarian Representatives from the African TB Caucus
P72 Perceived barriers and facilitators of isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Hae-Young Kim, Johns Hopkins Bloomberg School of Public Health, Maryland, United States

P52 HIV prevalence, TB treatment outcomes and determinants of default in adolescents and young adults treated for TB in Cape Town.
Pancho Mulongeni, The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

P53 Outcomes of efavirenz- and non-efavirenz containing ART in HIV-positive patients co-infected with tuberculosis in Eastern Europe, Western Europe and Latin America.
Brenda Crabtree-Ramírez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico

P54 Self-reported adherence to antiretroviral therapy predicts subsequent retention in care for extensively drug-resistant tuberculosis (XDR-TB) HIV co-infected patients on treatment in KwaZulu-Natal, South Africa.
Max O'Donnell, Columbia University, NY, United States

P55 Plasma cytokine predictors of TB recurrence in HIV-infected individuals on ART in Durban, South Africa.
Aida Sivro, Centre for the AIDS Programme of Research in South Africa (CAPRISA), KwaZulu-Natal, South Africa

P56 Provider-initiated HIV counselling and testing for patients with presumptive tuberculosis in Mandalay General Hospital, Myanmar, 2014-2015.
Nang Thu Thu Kyaw, International Union against Tuberculosis and Lung Disease, Mandalay, Myanmar

Olivier Marcy, Universite de Bordeaux, France

P59 Extensively drug resistant tuberculosis and HIV co-infection in KwaZulu-Natal, South Africa (the PROX study): treatment outcomes and molecular epidemiology.
Kay Yeungling, Columbia University, United States

P60 TB diagnosis with combined point-of-care tests in HIV+ patients in Mozambique.
Haswel Jere, DREAM Program, Italy

P61 Challenges to the integration of HIV and M/XDR-TB services in South Africa: a qualitative study of frontline health providers.
Amrita Daftary, McGill University, QC, Canada

P81 Intensified tuberculosis case-finding among people living with HIV under integrated HIV care program in upper Myanmar, 2015.
Khine Wut Yee Kyaw, International Union against Tuberculosis and Lung Disease, Mandalay, Myanmar

P82 The evolution of Mycobacterium tuberculosis in HIV co-infected individuals in an HIV/TB endemic setting.
Anastasia Koch, University of Cape Town, Western Cape, South Africa

O21 High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: The RAFA trial results.
Corinne Simone Merle, WHO, Switzerland
P17 Opportunity to reduce pre-diagnosis attrition among patients with presumptive MDR-TB in Bhopal district, India: an operational research.
Hemant Deepak Shewade, International Union against Tuberculosis and Lung Disease, None Selected, India

P18 “Finding” TB in India via active pharmacy engagement: early results from the IC-IMPACTS study.
Amrita Daftary, McGill University, QC, Canada

P19 Use of GeneXpert and household-based TB screening for detecting MDR TB in HIV-positive clients in two communities in Lusaka, Zambia during HPTN 071 (PopART study).
Ephraim Sakala, Zambart, Lusaka, Zambia

P20 Does level of access to healthcare predict loss to follow-up among tuberculosis patients? A multilevel study.
Laura Podewils, Centers for Disease Control and Prevention, Georgia, United States

P21 Intervention for patients interrupting rifampicin-resistant tuberculosis treatment for greater than two weeks: a descriptive analysis from Khayelitsha, South Africa.
Erika Mohr, Medecins Sans Frontieres, Western Cape, South Africa

P22 Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults.
Matthew Murray, Johns Hopkins Bloomberg School of Public Health, Maryland, United States

P23 Timing of contact tracing of household members of tuberculosis cases for optimal yield and resource allocation.
Laura Podewils, Centers for Disease Control and Prevention, Georgia, United States

Lindy Dickson-Hall, University of Cape Town, Western Cape, South Africa

P27 Screening for active TB in a diabetes mellitus clinic in Soweto, South Africa.
Jonathan Golub, Johns Hopkins School of Medicine, Maryland, United States

P28 Improving TB treatment outcomes in Matlosana and Ventersdorp sub-districts, Dr Kenneth Kaunda District, 2009 to 2014.
Georgina Wessie, University Research Co., LLC South Africa, South Africa

P29 Self-administered treatment for the continuation phase of rifampicin-resistant tuberculosis treatment: feasibility and impact on patient outcomes in Khayelitsha, South Africa.
Erika Mohr, Medecins Sans Frontieres, Western Cape, South Africa

P30 Universal Access to TB Care (UATBC): information technology platform to drive scale up in private sector engagement.
Rishabh Chopra, PATH, India

P31 Prevalence of and risk factors for diabetes mellitus among pulmonary tuberculosis patients in Pune, India.
Jonathan Golub, Johns Hopkins School of Medicine, Maryland, United States

P32 “Keeping-up with the DOTS”: patients’ perspectives of a financial incentive intervention to improve tuberculosis care: a qualitative study.
Kingsley Nnanna Ukwaja, Department of Medicine, Federal Teaching Hospital Abakaliki, Nigeria
MEASURING THE TB EPIDEMIC: WHAT IS THE BEST METHOD?
(PREVALENCE SURVEYS AND PROGRAMMATIC IMPLICATIONS)

P73 Autopsy prevalence of TB and other infections in adults with advanced HIV enrolled in out-patient care in South Africa.
Aaron S Karat, London School of Hygiene and Tropical Medicine, United Kingdom

P33 The childhood tuberculosis care cascade in HIV infected and uninfected children living in rural Uganda and Kenya.
Carina Marquez, University of California, San Francisco, California, United States

P34 Prevalence of latent TB infection among adults in endemic regions screened for a phase2b, double-blind, randomized, placebo-controlled study to evaluate GSK candidate vaccine M72/AS01E (NCT01755598).
Gretta Blatner, Aeras, MD, United States

ADVANCES IN UNDERSTANDING THE BASIC BIOLOGY OF TB

P71 Metabolomics - identifying small tuberculosis biomarkers with big implications.
Ilse Du Preez, North-West University, Northwest Province, South Africa

P74 Global transcriptional profiling elucidates significant up-regulation of host cytokines, chemokines and chemokine receptors by heparin binding hemagglutinin adhesin in BALB/c mice lungs.
Sumira Kuvar, University of KwaZulu-Natal, KwaZulu-Natal, South Africa

P75 Prevalence of inhA and KatG mutations and associated treatment outcomes among persons with multidrug resistant tuberculosis in Khayelitsha, South Africa.
Erika Mohr, Medecins Sans Frontieres, Western Cape, South Africa

P03 Unvisited players of eicosanoid pathway in Mycobacterium tuberculosis infection: cysteinyl leukotrienes.
Mumin Ozturk, University of Cape Town, South Africa

P04 Whole transcriptome analysis to elucidate the role of M. tuberculosis curli pili (MTP) on host gene regulation in a pulmonary epithelial cell model.
Mlungisi Dlamini, University of KwaZulu-Natal (NRMSM), KwaZulu-Natal, South Africa

P05 Growth of Mycobacterium tuberculosis in dead macrophages drives a host cell death cascade.
Deeqa Mahamed, K-RITH, KZN, South Africa

P76 Investigating the cost of rifampicin-resistance in mycobacteria.
Bevika Sewgoolam, University of Cape Town, Western Cape, South Africa

MDR AND XDR: DIAGNOSIS AND IMPACT (ABSTRACTS PRESENTED ORALLY IN ABSTRACT SESSION 1)

PREVENTION OF HIV-ASSOCIATED TB (ABSTRACTS PRESENTED ORALLY IN ABSTRACT SESSION 2)
UNDERSTANDING TB INFECTIOUSNESS AND TRANSMISSION

P02 Global transcriptome analysis reveals up-regulation of host cytokine genes, and cytokine and chemokine receptor binding in BALB/c mice by Mycobacterium tuberculosis curli pili (MTP).
Georgina Nyawo, University of KwaZulu-Natal, KwaZulu-Natal, South Africa

P66 Comparison of indoor contact time in Zambia and South Africa suggests targeting of interventions to reduce Mycobacterium tuberculosis transmission should be informed by local data.
Nicky McCreesh, London School of Hygiene and Tropical Medicine, United Kingdom

P67 A5300/I2003: feasibility of identifying, recruiting and characterizing adult MDR TB index cases and their adult and child household contacts on four continents.
Susan Swindells, University of Nebraska Medical Center, Nebraska, United States

P68 Extensively drug-resistant M. tuberculosis strains of the F15/LAM4/KZN genotype exhibit enhanced proinflammatory cytokine induction in THP-1 macrophages.
Charissa Camille Naidoo, Stellenbosch University, South Africa

NEW ADVANCES IN CLINICAL RESEARCH INCLUDING PEDIATRIC TB

P35 IMPAACT P1113/aeras C-015-404: Phase I/II study of H4:IC31 in BCG-primed infants
Avi Violari, Perinatal HIV Research Unit, Chris Hani Baragwaneth Hospital, University of the Witwatersrand, Soweto, South Africa

P36 Serial plasma cytokine levels in childhood tuberculosis: potential biomarkers for predicting therapeutic outcome.
Aparna Mukherjee, All India Institute of Medical Sciences (AIIMS), Delhi, India

P37 Initial management of MDR-TB in HIV co-infected patients in Eastern Europe: results from the TB:HIV study.
Anne Marie Werlinrud Efsen, Copenhagen Centre for Health and Infectious Disease Research (CHIP), Rigshospitalet, University of Copenhagen, Denmark

P38 Updated preliminary results of treatment of multidrug-resistant tuberculosis (MDR-TB) with a 9-month regimen in francophone Africa.
Valerie Schwoebel, International Union Against Tuberculosis & Lung Disease, Not Applicable, France

NEW TOOLS, R&D DRUGS, DIAGNOSTICS AND VACCINES

P01 Use of QuantIFERON ®-TB Gold assay in clinical trials: effect of immediate incubation and temperature variations during transportation on assay outcomes.
Maureen Lambrick, Aeras Africa, South Africa

P70 Resolution of discordant rifampicin genotypic and phenotypic drug susceptibility testing in TB/HIV co-infected patients.
Bianca Sansom, National Institute for Communicable Diseases, Gauteng, South Africa

P39 Prevalence of bedaquiline resistance-conferring mutations in drug resistant tuberculosis patients in South Africa.
Lavania Joseph, National Institute for Communicable Diseases, Gauteng, South Africa

P41 Development of an in-house single step loop mediated isothermal amplification assay for the detection of Mycobacterium tuberculosis complex in sputum samples from moroccan patients.
El Mehdi Bentaleb, Moroccan Foundation for Advanced Science, Innovation and Research (MAScIR), Rabat, Morocco
P42 Affordability of comprehensive MDR-TB treatment with novel regimens, at current prices versus estimated competitive generic prices.
Dzintars Gotham, Imperial College London, United Kingdom

P43 Laboratory detection of rifampicin low level resistance in Mycobacterium tuberculosis.
Nomonde Ritta Mvelase, University of KwaZulu-Natal & National Health Laboratory Service, KwaZulu-Natal, South Africa

P44 Evaluation of the fluorotype MTB assay for detection of Mycobacterium tuberculosis complex DNA in fineneedle aspiration biopsy (FNAB) specimens.
Sharlene Govender, Nelson Mandela Metropolitan University, Eastern Cape, South Africa

P45 DNA extracted from used Xpert MTB/RIF cartridges can be used for second-line drug susceptibility testing.
Rouxjeane Venter, Stellenbosch University, Western Cape, South Africa

P46 Identification of biomarkers predictive of early stage tuberculosis infection.
Eustache Paramithiotis, Caprion Biosciences Inc, Quebec, Canada

P47 Effect of sputum quality and volume on the yield of bacteriologically confirmed TB by Xpert and smear microscopy among people living with HIV in Botswana.
Onani Zimba, CDC Botswana, Botswana

P48 Early morning urine collection to improve urinary LAM lateral flow assay sensitivity in hospitalised patients with HIV-TB co-infection.
Phindile Gina, Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Western Cape, South Africa

P49 Evaluation of Anyplex II™ MTB/MDR-TB for rapid detection of multidrug resistant tuberculosis (MDR-TB) on clinical sediments.
Tsireledzo Raidani, Sefako Makgatho Health Science University, South Africa

P50 Comparison between Bedaquiline minimum inhibitory concentrations using the agar proportion method and the Sensititre broth microdilution method.
Tracy Arendse, National Institute for Communicable Diseases, Gauteng, South Africa

P51 Decreased sensitivity and increased indeterminate rates of GenoType MTBDRplus (v2.0) are associated with use of inappropriate PCR ramp rate: implications for routine diagnostic laboratories.
Brigitta Derendinger, Stellenbosch University, Western Cape, South Africa

COMMUNITY ENGAGEMENT AND INNOVATIONS

P07 Lessons learned with the implementation of household TB screening, diagnosis and initiation of TB treatment in South Africa.
Francionette Esau, University of Stellenbosch, Western Cape, South Africa

P08 Building the capacity of local language media to report on TB.
Amy Israel, Lilly MDR-TB Partnership and Eli Lilly & Co. Ltd., Switzerland

P09 Impact of directly-observed treatment support offered by local NGO in Mahikeng Sub-district, Ngaka Modiri Molema District, North West Province, 2013 – 2014.
Georgina Wessie, University Research Co., LLC South Africa, South Africa

P10 Improving the quality of data to improve TB treatment outcomes in Sub-district A, Nelson Mandela Bay Health District, South Africa.
Liziwe Canzibe, University Research Co., LLC South Africa, South Africa
P11 Tackling TB in early childhood development centres in Ethekwini Metro, KwaZulu Natal, South Africa.
Fikile Dlongolo, University Research Co., LLC South Africa, South Africa

P12 Introduction of TB screening services in 17 correctional setting through a non-governmental organization.
Claire Rademayer, Footballers 4 Life, South Africa

P13 Active case finding revealing the hidden face of tuberculosis within 80 slum areas in Oyo State of Nigeria.
Samuel Okunoye Okewoye, MATHAMAN, Oyo State, Nigeria

P14 Advancing towards TB elimination - significant contribution by rural health care providers (RHCPs) to national TB program using mobile technology in Tribal District of India.
Archana Trivedi, USEA The Union, Delhi, India

P15 A pilot study to evaluate the experiences of TB patients when accessing TB services in five health facilities in Kisumu – Kenya.
Edgar Makona, KELIN, Kenya

P16 Treatment adherence among TB patients in the private sector - combination of technology and human touch.
Rishabh Chopra, PATH, India

P77 Tuberculosis eCurriculum series: a web-based self-paced education program.
Zelalem Temesgen, Mayo Clinic, Minnesota, United States

P78 Eh!woza.
Anastasia Koch, University of Cape Town, Western Cape, South Africa

P80 Beyond the lab and behind the lens: an exploration of a community engagement initiative and its reflection of the lived experience of TB in Khayelitsha.
Bianca Masuku, University of Cape Town, Western Cape, South Africa

P83 Disease surveillance through mobile phones: Geotagging the ‘smart-phone’ way.
Rishabh Chopra, PATH, India

TRANSLATIONAL RESEARCH

P64 Lung tissue resident T cell immune responses to Mycobacterium tuberculosis infection in humans
Paul Ogongo, Kwa-Zulu Natal Research Institute for TB and HIV, South Africa

TRANSMISSION AND DIAGNOSIS (ABSTRACTS PRESENTED ORALLY IN ABSTRACT SESSION 3)

PAEDIATRIC MDR TB AND CLINICAL EPIDEMIOLOGY (ABSTRACTS PRESENTED ORALLY IN ABSTRACT SESSION 4)

COMMUNITY ENGAGEMENT AND INNOVATIONS (ABSTRACTS PRESENTED ORALLY IN ABSTRACT SESSION 5)
PARTNERS
International AIDS Society
World Health Organization
Stop TB Partnership
The UN Special Envoy on TB

RESULTS
ACTION Global Health Advocacy Partnership
The International Union Against Tuberculosis and Lung Disease

CO-CHAIRS
Jens Lundgren
Director of the Centre for Health and Infectious Disease Research, University of Copenhagen

Valerie Mizrahi
Director of the Institute of Infectious Disease and Molecular Medicine, University of Cape Town

Haileyesus Getahun
Coordinator, Global TB Programme, World Health Organization

SCIENTIFIC STEERING COMMITTEE MEMBERS
Alberto Matteelli
University of Brescia

Alison Grant
London School of Hygiene & Tropical Medicine

Ajay Kumar
International Union Against Tuberculosis and Lung Disease

Ann Ginsberg
Aeras

Anneke Hesseling
Desmond Tutu TB Centre

Anthony Harries
International Union Against Tuberculosis and Lung Disease

Beatrice Mutayoba
National Institute for Medical Research, Tanzania

Carol Hamilton
Duke University

Clifton Barry
United States National Institutes of Health

Daria Podlekaeva
Nordsjaellands Hospital, Hilleroed and Rigshospitalet

Diane Havlir
University of California, San Francisco

Eliud Wandwalo
The Global Fund to Fight AIDS, Tuberculosis and Malaria

Eric Goosby
UN Special Envoy on TB

Erica Lessem
Treatment Action Group

Gilla Kaplan
Bill & Melinda Gates Foundation

Jason Andrews
Stanford University

Jeremiah Chakaya
Kenya Medical Research Institute

Joanne Carter
RESULTS

Kevin Cain
Kenya Medical Research Institute

Linda-Gail Bekker
Desmond Tutu HIV Centre

Luis Soto-Ramirez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Michael Kimerling
KNCV Foundation

Owen Ryan
International AIDS Society

Paula Fujiwara
International Union Against Tuberculosis and Lung Disease

Richard Chaisson
Johns Hopkins University

Robin Wood
Desmond Tutu HIV Centre, University of Cape Town

Sahu Suvanand
Stop TB Partnership

Soumya Swaminathan
Indian Council of Medical Research

Stefan Kaufmann
Max Planck Institute for Infection Biology

Stephen Lawn
London School of Hygiene & Tropical Medicine

Stewart Cole
École Polytechnique Fédérale de Lausanne

Zelalem Temesgen
Mayo Clinic